Polyrizon Reports Preclinical Results For PL-14 Allergy Blocker, Showing Over 60% Targeted Nasal Deposition

Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product's potential as a barrier-forming treatment for allergic rhinitis.

The evaluation was led by Professor Fabio Sonvico from the Department of Food and Drug at the University of Parma, a leading authority in intranasal and pulmonary drug delivery and a member of Polyrizon's Scientific Advisory Board. Using a validated silicone-based human nasal cast and fluorescein-labeled imaging, the study assessed the spray deposition profile of PL-14 when administered under clinically relevant conditions.

The results revealed that the PL-14 formulation achieved over 60% deposition in the nasal vestibule, the first physiological region exposed to airborne allergens. This targeted delivery is critical for effectively blocking allergen contact with the nasal mucosa, supporting the mechanism of action of PL-14 as a physical barrier product designed to capture and contain environmental allergens before they trigger an immune response.